Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
External Validation of Prognostic Rules for 30-Day Post-Pulmonary Embolism Mortality: Assessment of a Claims-Based and Three Clinical-Based Approaches
2016
Research Type: Poster/Presentation
Impact of Dosing Frequency on Adherence to Chronic Cardiovascular Medications: A Meta-Regression Analysis
2016
Research Type: Poster/Presentation
External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer
2016
Research Type: Poster/Presentation
External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans
2016
Research Type: Poster/Presentation
Is rivaroxaban associated with shorter hospital stays and reduced costs versus parenteral bridging to warfarin among patients with pulmonary embolism?
2016
Research Type: Poster/Presentation
Association Between Weekend Admission for Atrial Fibrillation or Flutter and In-hospital Mortality, Procedure Utilization, Length-of-stay and Treatment Costs
2016
Research Type: Poster/Presentation
Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis
2016
Research Type: Poster/Presentation
Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation in the United States: the REVISIT-US study
2016
Research Type: Poster/Presentation
External Validation of the Hesta Criteria for Identifying Acute Pulmonary Embolism Patients at Low-Risk of Early Mortality
2016
Research Type: Poster/Presentation
Adherence to Rivaroxaban and Dabigatran in Nonvalvular Atrial Fibrillation Patients in the United States
2016
Research Type: Poster/Presentation
Abstract 13140: Effectiveness of Rivaroxaban among Patients Diagnosed With Pulmonary Embolism
2016
Research Type: Poster/Presentation
Is Rivaroxaban Associated with Shorter Inpatient Stays and Lower Hospital Treatment Costs Compared to Heparin Bridging to Warfarin in Low-Risk Pulmonary Embolism Patients?
2016
Research Type: Poster/Presentation
External Validation of Prognostic Rules for In-Hospital Post-Pulmonary Embolism Mortality: Assessment of a Claims-Based and Three Clinical-Based Approaches
2016
Research Type: Poster/Presentation
Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status
2016
Research Type: Poster/Presentation
Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism
2016
Research Type: Poster/Presentation
How does the Real World Use of Factor Xa Inhibitors Compare to Trial Data in Stroke Prevention?
2016
Research Type: Poster/Presentation
Is rivaroxaban associated with shorter hospital stays and reduced costs vs. parenteral bridging to warfarin among pulmonary embolism patients?
2016
Research Type: Poster/Presentation
Impact of magnesium l-lactate on occurrence of ventricular arrhythmias in patients with implantable cardioverter defibrillators: a randomized, placebo-controlled trial
2015
Research Type: Journal Article
Derivation and validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule.
2015
Research Type: Journal Article